London-listed Agronomics has made a further AU$3 million (around £1.47m) investment in Australian MedTech All G, which uses precision fermentation to produce animal-free human and bovine milk proteins such as lactoferrin.

The funding forms part of a minimum AU$10m round and will support commercial-scale production, regulatory work, patents and expansion into Asia and Europe.

All G has already secured key regulatory milestones, including clearance in China for recombinant bovine lactoferrin and GRAS status in the US, with launches planned in both markets in Q1 2026.

The firm will fund the deal via a convertible note and issue just over 10m new shares, taking its total investment in All G to around £8.9m.